CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury. / Ashina, Håkan; Iljazi, Afrim; Al-Khazali, Haidar M.; Do, Thien Phu; Eigenbrodt, Anna K.; Larsen, Eigil L.; Andersen, Amalie M.; Hansen, Kevin J.; Bräuner, Karoline B.; Chaudhry, Basit Ali; Christensen, Casper E.; Amin, Faisal Mohammad; Schytz, Henrik W.

I: Journal of Headache and Pain, Bind 23, Nr. 1, 135, 2022.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Ashina, H, Iljazi, A, Al-Khazali, HM, Do, TP, Eigenbrodt, AK, Larsen, EL, Andersen, AM, Hansen, KJ, Bräuner, KB, Chaudhry, BA, Christensen, CE, Amin, FM & Schytz, HW 2022, 'CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury', Journal of Headache and Pain, bind 23, nr. 1, 135. https://doi.org/10.1186/s10194-022-01499-5

APA

Ashina, H., Iljazi, A., Al-Khazali, H. M., Do, T. P., Eigenbrodt, A. K., Larsen, E. L., Andersen, A. M., Hansen, K. J., Bräuner, K. B., Chaudhry, B. A., Christensen, C. E., Amin, F. M., & Schytz, H. W. (2022). CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury. Journal of Headache and Pain, 23(1), [135]. https://doi.org/10.1186/s10194-022-01499-5

Vancouver

Ashina H, Iljazi A, Al-Khazali HM, Do TP, Eigenbrodt AK, Larsen EL o.a. CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury. Journal of Headache and Pain. 2022;23(1). 135. https://doi.org/10.1186/s10194-022-01499-5

Author

Ashina, Håkan ; Iljazi, Afrim ; Al-Khazali, Haidar M. ; Do, Thien Phu ; Eigenbrodt, Anna K. ; Larsen, Eigil L. ; Andersen, Amalie M. ; Hansen, Kevin J. ; Bräuner, Karoline B. ; Chaudhry, Basit Ali ; Christensen, Casper E. ; Amin, Faisal Mohammad ; Schytz, Henrik W. / CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury. I: Journal of Headache and Pain. 2022 ; Bind 23, Nr. 1.

Bibtex

@article{4d6e8b4cf48545c190093ada5be49f02,

title = "CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury",

abstract = "Objective: To ascertain whether intravenous infusion of calcitonin gene-related peptide (CGRP) can induce migraine-like headache in people with persistent post-traumatic headache attributed to mild traumatic brain injury (TBI) and no pre-existing migraine. Methods: A non-randomized, single-arm, open-label study at a single site in Denmark. Eligible participants were aged 18 to 65 years and had a known history of persistent post-traumatic headache attributed to mild TBI for ≥ 12 months. All participants received continuous intravenous infusion of CGRP (1.5 µg/min) over 20 min. A headache diary was used to collect outcome data until 12 h after the start of CGRP infusion. The primary end point was the incidence of migraine-like headache during 12-hour observational period. Results: A total of 60 participants completed the study protocol and provided data for the analysis of the primary end point. The median age was 32.5 (IQR, 25.5–43.0) years; 43 participants (72%) were female. Following CGRP infusion, 43 (72%) of 60 participants developed migraine-like headache during the 12-hour observational period. The median time to peak headache intensity was 40 min (IQR, 20–60), and the median peak headache intensity was 6 (IQR, 5–8) on the 11-point numeric rating scale. Conclusion: Intravenous infusion of CGRP is a potent inducer of migraine-like headache in people with persistent post-traumatic headache attributed to mild TBI. This observation underscores the importance of CGRP in the genesis of migraine-like headache that is often experienced by individuals who are afflicted by persistent post-traumatic headache. Further research is warranted to ascertain whether other signaling molecules also contribute to the disease mechanisms underlying post-traumatic headache.",

keywords = "CGRP, Concussion, Migraine, Pathophysiology, Trigeminovascular System",

author = "H{\aa}kan Ashina and Afrim Iljazi and Al-Khazali, {Haidar M.} and Do, {Thien Phu} and Eigenbrodt, {Anna K.} and Larsen, {Eigil L.} and Andersen, {Amalie M.} and Hansen, {Kevin J.} and Br{\"a}uner, {Karoline B.} and Chaudhry, {Basit Ali} and Christensen, {Casper E.} and Amin, {Faisal Mohammad} and Schytz, {Henrik W.}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

doi = "10.1186/s10194-022-01499-5",

language = "English",

volume = "23",

journal = "Journal of Headache and Pain",

issn = "1129-2369",

publisher = "SpringerOpen",

number = "1",

}

RIS

TY - JOUR

T1 - CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury

AU - Ashina, Håkan

AU - Iljazi, Afrim

AU - Al-Khazali, Haidar M.

AU - Do, Thien Phu

AU - Eigenbrodt, Anna K.

AU - Larsen, Eigil L.

AU - Andersen, Amalie M.

AU - Hansen, Kevin J.

AU - Bräuner, Karoline B.

AU - Chaudhry, Basit Ali

AU - Christensen, Casper E.

AU - Amin, Faisal Mohammad

AU - Schytz, Henrik W.

PY - 2022

Y1 - 2022

N2 - Objective: To ascertain whether intravenous infusion of calcitonin gene-related peptide (CGRP) can induce migraine-like headache in people with persistent post-traumatic headache attributed to mild traumatic brain injury (TBI) and no pre-existing migraine. Methods: A non-randomized, single-arm, open-label study at a single site in Denmark. Eligible participants were aged 18 to 65 years and had a known history of persistent post-traumatic headache attributed to mild TBI for ≥ 12 months. All participants received continuous intravenous infusion of CGRP (1.5 µg/min) over 20 min. A headache diary was used to collect outcome data until 12 h after the start of CGRP infusion. The primary end point was the incidence of migraine-like headache during 12-hour observational period. Results: A total of 60 participants completed the study protocol and provided data for the analysis of the primary end point. The median age was 32.5 (IQR, 25.5–43.0) years; 43 participants (72%) were female. Following CGRP infusion, 43 (72%) of 60 participants developed migraine-like headache during the 12-hour observational period. The median time to peak headache intensity was 40 min (IQR, 20–60), and the median peak headache intensity was 6 (IQR, 5–8) on the 11-point numeric rating scale. Conclusion: Intravenous infusion of CGRP is a potent inducer of migraine-like headache in people with persistent post-traumatic headache attributed to mild TBI. This observation underscores the importance of CGRP in the genesis of migraine-like headache that is often experienced by individuals who are afflicted by persistent post-traumatic headache. Further research is warranted to ascertain whether other signaling molecules also contribute to the disease mechanisms underlying post-traumatic headache.

AB - Objective: To ascertain whether intravenous infusion of calcitonin gene-related peptide (CGRP) can induce migraine-like headache in people with persistent post-traumatic headache attributed to mild traumatic brain injury (TBI) and no pre-existing migraine. Methods: A non-randomized, single-arm, open-label study at a single site in Denmark. Eligible participants were aged 18 to 65 years and had a known history of persistent post-traumatic headache attributed to mild TBI for ≥ 12 months. All participants received continuous intravenous infusion of CGRP (1.5 µg/min) over 20 min. A headache diary was used to collect outcome data until 12 h after the start of CGRP infusion. The primary end point was the incidence of migraine-like headache during 12-hour observational period. Results: A total of 60 participants completed the study protocol and provided data for the analysis of the primary end point. The median age was 32.5 (IQR, 25.5–43.0) years; 43 participants (72%) were female. Following CGRP infusion, 43 (72%) of 60 participants developed migraine-like headache during the 12-hour observational period. The median time to peak headache intensity was 40 min (IQR, 20–60), and the median peak headache intensity was 6 (IQR, 5–8) on the 11-point numeric rating scale. Conclusion: Intravenous infusion of CGRP is a potent inducer of migraine-like headache in people with persistent post-traumatic headache attributed to mild TBI. This observation underscores the importance of CGRP in the genesis of migraine-like headache that is often experienced by individuals who are afflicted by persistent post-traumatic headache. Further research is warranted to ascertain whether other signaling molecules also contribute to the disease mechanisms underlying post-traumatic headache.

KW - CGRP

KW - Concussion

KW - Migraine

KW - Pathophysiology

KW - Trigeminovascular System

UR - http://www.scopus.com/inward/record.url?scp=85140029380&partnerID=8YFLogxK

U2 - 10.1186/s10194-022-01499-5

DO - 10.1186/s10194-022-01499-5

M3 - Journal article

C2 - 36253732

AN - SCOPUS:85140029380

VL - 23

JO - Journal of Headache and Pain

JF - Journal of Headache and Pain

SN - 1129-2369

IS - 1

M1 - 135

ER -

ID: 329248761